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Objective. Recent evidence has highlighted a ma-
jor genetic contribution to radiographic damage in
rheumatoid arthritis (RA). The objective of this study
was to determine whether genetic variants in the loci for
interleukin-1 (IL-1), IL-6, IL-10, protein tyrosine phos-
phatase N22 (PTPN22), and selenoprotein S are asso-
ciated with radiographic damage.
Methods. Modified Larsen scores of radiographic
damage were determined in a cross-sectional population
of patients with RA (n  964). Rheumatoid factor (RF)
and anti–cyclic citrullinated peptide (anti-CCP) were
also assayed. The Kruskal-Wallis nonparametric test
was used to compare median radiographic damage
scores across genotype groups, followed by the Cuzick
nonparametric test for trend to assess gene-dose effects.
Results. An allele-dose association of IL-6 174G
with increasing radiographic damage was present (P 
0.005), but only in patients who were RF positive (P 
0.004) or anti-CCP positive (P  0.01). Patients with the
IL-10 592CC genotype had more extensive radio-
graphic damage than did those with the AC or AA
genotype (P  0.006), but this was observed only among
patients who were RF negative (P  0.002) or anti-CCP
negative (P  0.002). However, RF status and anti-CCP
status were not associated with the IL-6 or IL-10
genotype. No other genetic associations were detected,
apart from a marginal association of PTPN22 1858T
with increased radiographic damage.
Conclusion. The reported associations of IL-6
174G with high IL-6 production and IL-10 592 with
low IL-10 production and our own results support a role
of genetically determined dysregulated cytokine produc-
tion in disease severity. The lack of association of these
genotypes with RF and anti-CCP antibody status sug-
gests that they act downstream of autoantibody produc-
tion. We conclude that IL-6 and IL-10 genotypes may be
useful in predicting disease severity in autoantibody-
positive and autoantibody-negative patients, respec-
tively.
Rheumatoid arthritis (RA) is the most common
autoimmune inflammatory joint disease, with a preva-
lence of 1%. The etiology of RA is multifactorial and
includes a significant genetic component, with a relative
risk of recurrence of 5–10 in siblings of probands (1).
Many genetic linkage and association studies have im-
plicated a group of alleles of the DRB1 gene encoding a
similar sequence, termed the shared epitope (2,3). Re-
cent evidence has also implicated the common allele of
the R620W single-nucleotide polymorphism (SNP)
(rs2476601) in the hematopoietic-specific protein ty-
rosine kinase, protein tyrosine phosphatase N22
(PTPN22), with susceptibility to several autoimmune
diseases, including RA (4).
The severity of RA varies from mild self-limiting
arthritis to an aggressive systemic disease associated with
a significantly reduced life expectancy. Several validated
systems for scoring radiographic damage are widely used
to assess disease progression or severity, including the
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2549Sharp and Larsen scores (5,6). More severe radiographic
damage correlates with the presence of rheumatoid
factor (RF) and anti–cyclic citrullinated peptide (anti-
CCP) antibodies, with the presence of both being asso-
ciated with more severe changes compared with the
presence of either of the biomarkers alone (7). Longi-
tudinal studies have revealed a strong correlation of
total inflammation load, as assessed by C-reactive pro-
tein (CRP) levels over time, with greater radiographic
damage (8). A recent report described the usefulness of
measurement, at the time of disease presentation, of a
range of biomarkers, including RF, anti-CCP antibodies,
DRB1 alleles, and CRP and suggested that these vari-
ables could be used to predict damage to the hand and
foot joints; however, the variance of radiographic joint
damage that could be explained by these measurements
was only 44% at 5 years and only 32% at 10 years,
suggesting that other variables contribute to joint dam-
age (9).
Relatively few studies have addressed the role of
genetics in relation to radiographic joint damage. A
small study compared the radiographic progression in
monozygotic twins, dizygotic twins, and unrelated pairs
of patients and found that variation was maximal in
unrelated patients, followed by dizygotic twins, and was
least in monozygotic twins, suggesting genetic input (10).
A relationship between DRB1 alleles and disease sever-
ity has been reported, but recent evidence suggests that
it is secondary to production of anti-CCP antibodies
(11), particularly in RF-negative patients (5). Many
studies have shown genetic associations with RA sever-
ity; however, these studies used different criteria to
measure disease severity, such as the presence of rheu-
matoid nodules, a history of joint replacement surgery,
earlier age at disease onset, or radiographic scoring
methods. Furthermore, they mostly involved relatively
small numbers of patients and did not assess the rela-
tionship with established biomarkers such as autoanti-
bodies (12).
A central feature of RA is a relative imbalance of
cytokine production, with a relative excess of proinflam-
matory molecules including interleukin-1 (IL-1), IL-6,
and tumor necrosis factor (TNF) compared with antiin-
flammatory mediators such as IL-10 (13). The successful
therapeutic use of inhibitors of proinflammatory cyto-
kines underlines the importance of these molecules in
driving rheumatoid inflammation and tissue damage.
The production of these molecules is controlled at the
levels of transcription, messenger RNA stability, and
translational efficiency. Recently, selenoprotein S
(SEPS) was identified as an important regulator of IL-1,
TNF, and IL-6, with plasma levels of these proteins
correlating with functional promoter single-nucleotide
polymorphisms (SNPs) in SEPS (14).
In this genetic study, we examined whether SNPs
in IL-1, IL-6, IL-10, PTPN22, and SEPS are associated
with radiographic damage in a large cross-sectional
cohort of patients with RA, and determined whether the
associations detected were independent of production of
RF and anti-CCP. Variants were chosen based on
previous reports of functional relevance or associations
with RA.
PATIENTS AND METHODS
Patients. Nine hundred sixty-four patients fulfilling the
American College of Rheumatology (formerly, the American
Rheumatism Association) criteria for the classification of RA
(15) were recruited from the Royal Hallamshire Hospital,
Sheffield, as previously described; 872 of these patients had
erosive damage (5). Research Ethics Committee approval was
obtained for the study, and all participants provided informed
consent. Radiographs of the hands and feet were obtained at
the time of study entry, and modified Larsen scores of
radiographic damage progression were obtained as described
previously (5,6).
Measurement of antibodies. Measurement of antibod-
ies was performed as previously described (5). Briefly, anti-
CCP antibody levels were measured using the DIASTAT
Anti-CCP enzyme-linked immunosorbent assay (Axis-Shield
UK, Kimbolton, UK). A cutoff of 5.5 units/ml was established
to define antibody positivity, based on the mean (3 SD) of
values obtained for 100 age-matched control subjects. RF was
measured using a Dade-Behring BN2 nephelometer (Marburg,
Germany).
Genotyping. Genotyping of SNPs in the IL-1 gene
cluster, IL-6, IL-10, PTPN22, SEPS 3705, and SEPS 5227
was performed using TaqMan assays designed by Applied
Biosystems (Foster City, CA) (Table 1). Typing of SEPS 105
was performed commercially by personnel at KBiosciences
(Herts, UK) using the KASPar method (http://
kbioscience.co.uk/chemistry/index.htm) and primers 5-
Table 1. Details of individual single-nucleotide polymorphisms
(SNPs)
SNP number Gene Description
rs17561 IL1 Ser
114Ala
rs16944 IL1 Promoter (511)
rs1143634 IL1 Synonymous coding, Phe
105Phe
rs419598 IL1RN Synonymous coding, Ala
39Ala
rs1800872 IL10 Promoter (592)
rs1800896 IL10 Promoter (1082)
rs1800795 IL6 Promoter (174)
rs2476601 PTPN22 Arg
620Trp
Not applicable SEPS 5-untranslated region
rs4965814 SEPS Intron 5
rs4965373 SEPS 3-untranslated region
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CYTOKINE GENETIC ASSOCIATIONS WITH MODIFIED LARSEN SCORES 2551GGACGCGGTCGTGGTCCC-3 (C allele), 5-
GGACGCGGTCGTGGTCCT-3 (T allele), and common
primer 5-GGTCGGCCTGCGATTGGCC-3. To ensure
high-quality genotyping results, we included multiple positive
controls (sequenced templates) and negative controls (ultra-
pure water templates) in all genotyping plates, 10% of assays
were repeated for quality control purposes, and no discrepan-
cies were found. One allelic TaqMan probe was labeled with
fluorescent FAM dye and the other with VIC dye (Table 2).
The total reaction volume was 5 l, containing 10 ng of
genomic DNA. Thermal cycling in 384-well plates was per-
formed using a PTC-225 DNA Engine Tetrad thermal cycler
(MJ Research, San Francisco, CA), and genotypes were de-
termined using an ABI Prism 7900HT Sequence Detection
System (Applied Biosystems).
Statistical analysis. Hardy-Weinberg equilibrium was
examined using the chi-square goodness-of-fit test. Pearson’s
chi-square test was used to compare allele/genotype carrier-
ship between patients and control subjects, and crude odds
ratios are presented with 95% confidence intervals. For each
DNA variant, the most prevalent homozygous genotype was
chosen as the baseline reference.
Dichotomized variables were created for RF and anti-
CCP levels (for RF positivity, 40 IU/ml; for anti-CCP
positivity, 5.5 units/ml), and Pearson’s chi-square test was
used to test for association between allele/genotype and auto-
antibody seropositivity in patients with RA. Larsen scores of
radiographic damage in patients with RA were tested for
associations with candidate gene polymorphisms as well as RF
and anti-CCP. The Shapiro-Francia test for normality was
applied to the data and showed strong evidence against the
assumption of normality for the modified Larsen score distri-
bution.
The Kruskal-Wallis nonparametric test was therefore
used to compare median scores across genotype groups, fol-
lowed by the Cuzick nonparametric test for trend to assess
gene-dose effects. Genotypes were coded as 0, 1, and 2 for the
most prevalent homozygous, heterozygous, and variant ho-
mozygous genotypes, respectively. Quantile regression was
carried out to estimate the proportion of variance of the
different variables in relation to the modified Larsen score.
Quantile regression is a complement to classic linear regres-
sion, in which the primary goal is to determine the conditional
mean of a random variable y, given some explanatory variable
x. In quantile regression, one determines the conditional
quantile distribution of the y variable; of most common interest
is measurement of the 50% quantile or median. All statistical
analyses were carried out using Stata statistical software,
release 9.1 (Stata Corporation, College Station, TX).
RESULTS
The study cohort consisted of 964 patients, whose
characteristics at baseline are detailed in Table 3. Geno-
typing data for the SEPS 105 SNP were available for
509 patients; for all other markers, data were available
for 856–940 patients in the cohort (89–98%). All geno-
typing results fit Hardy-Weinberg equilibrium. Because
Larsen scores did not fit a normal distribution, we
compared median scores across the 3 genotypes. The
Shapiro-Francia test for normality was applied to the
data and showed strong evidence against the assumption
Table 4. Genotypes and modified Larsen scores of radiographic
damage
Gene Genotype
Patients,
no. (%)
Median
modified
Larsen score* P
PTPN22 (n  901) TT 31 (3.4) 50.0
TC 238 (26.4) 33.0 0.04†
CC 632 (70.1) 25.5
IL10 592 (n  928) AA 32 (3.4) 27.5
AC 309 (33.3) 22.0 0.006
CC 587 (63.3) 32.0
IL10 1082 (n  860) AA 186 (21.6) 24.0
AG 415 (48.3) 27.0 0.01†
GG 259 (30.1) 31.0
IL1RN (n  831) CC 39 (4.7) 36.0
TC 334 (40.2) 29.0 0.4†
TT 458 (55.1) 27.5
IL6 174 (n  930) CC 166 (17.8) 25.0
CG 482 (51.8) 27.0 0.005†
GG 282 (30.3) 33.5
IL1 511 (n  932) GG 89 (9.5) 33.0
GA 421 (45.2) 27.0 0.8
AA 422 (45.3) 28.0
IL1 3954 (n  880) TT 37 (4.2) 49.0
TC 332 (37.7) 22.0 0.1
CC 511 (58.1) 29.0
IL1 4845 (n  916) TT 64 (7.0) 31.0
GT 398 (43.4) 27.0 0.8
GG 454 (49.6) 28.0
SEPS 105 (n  509) TT 8 (1.6) 49.5
CT 128 (25.1) 31.0 0.6
CC 373 (73.3) 33.0
SEPS 3705 (n 
934)
TT 24 (2.6) 44.5
CT 282 (30.2) 28.0 0.2
CC 628 (67.2) 28.0
SEPS 5227 (n 
888)
GG 99 (11.1) 27.0
GA 398 (44.8) 30.5 0.4
AA 391 (44.0) 26.0
* Maximum possible score is 160.
† By Cuzick’s test for trend.
Table 3. Baseline clinical characteristics of the patients with rheu-
matoid arthritis*
No. of patients 964
Age, mean  SD years 61.3  12.3
Disease duration, mean  SD years 15.6  10.7
Female sex, no. (%) 695 (72.1)
Male sex, no. (%) 269 (27.9)
Rheumatoid factor positive, no. (%) 604 (68.4)
Rheumatoid factor negative, no. (%) 279 (31.6)
Anti–cyclic citrullinated peptide positive, no. (%) 697 (76.3)
Anti–cyclic citrullinated peptide negative, no. (%) 217 (23.7)
* Rheumatoid factor status was determined in 883 patients, while
antibody status was determined in 914 patients.
2552 MARINOU ET ALof normality for Larsen score distribution. The Kruskal-
Wallis nonparametric test was then applied to test for
median Larsen score differences across genotypes of
each variant, followed by the Cuzick nonparametric test
for trend when a gene-dose effect was observed. Geno-
types were coded as 0, 1, and 2 for the most prevalent
homozygous, heterozygous, and variant homozygous
genotypes, respectively.
The frequency of the IL-6 174G allele was 55%,
and an allele-dose association with increasing radio-
graphic damage was present (P  0.005), with patients
with the GG genotype having the highest median mod-
ified Larsen score (Table 4). Strong linkage disequili-
brium was detected between the 2 IL-10 SNPs (D
0.89 and r
2  0.24), with allele frequencies of 55% and
79% for IL-10 1082G and 592, respectively. The
IL-10 592CC genotype was associated with greater
damage compared with the AC genotype, and the AA
genotype was associated with an intermediate score for
damage (P  0.006). An allele-dose association of IL-10
1082 with damage was observed, but the difference in
median scores between genotypes (P  0.01) was less
than that for IL-10 592. A relatively weak association
of PTPN22 1858T was detected (P  0.04). The allele
frequency of PTPN22 1858T was 17%, and only a
small number of patients had the TT genotype. Radio-
Table 5. Genotype frequencies and autoantibody status*
Gene Genotype
Anti-CCP
positive
Anti-CCP
negative OR (95% CI) P
RF
positive
RF
negative OR (95% CI) P
PTPN22 1858 TT 29 2 5.2 (1.3–45.7) 0.01† 23 5 2.2 (0.8–7.4) 0.1†
TC 177 50 1.3 (0.9–1.9) 138 76 0.9 (0.6–1.2) 0.3
CC 446 161 404 190
IL10 592 AA 28 6 1.5 (0.6–4.5) 0.5† 25 8 1.4 (0.6–3.7) 0.6†
AC 222 72 1.0 (0.7–1.4) 0.9 191 96 0.9 (0.7–1.2) 0.5
CC 432 138 375 169
IL10 1082 AA 138 36 1.1 (0.7–1.9) 0.6 120 52 1.1 (0.7–1.8) 0.6
AG 291 113 0.8 (0.5–1.1) 0.2 253 129 1.0 (0.7–1.4) 0.8
GG 191 57 159 78
IL6 174 CC 120 40 0.9 (0.6–1.5) 0.7 98 56 0.7 (0.5–1.1) 0.1
CG 351 112 1.0 (0.7–1.4) 0.9 304 140 0.9 (0.6–1.3) 0.6
GG 207 64 184 77
* The presence of anti–cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) was compared for each single-nucleotide polymorphism
with reference to the commonest genotype. OR  odds ratio; 95% CI  95% confidence interval.
† By Fisher’s exact test for association.
Table 6. Modified Larsen scores across genotypes, according to anti-CCP and RF status*
Anti-CCP positive Anti-CCP negative RF positive RF negative
PTPN22 1858
TT/TC 31.0 (206) 20.0 (50) 42.0 (161) 19.0 (81)
CC 37.5 (445) 8.5 (158) 33.5 (404) 13.0 (188)
P 0.5 0.04 0.2 0.07
IL10 592
AA/AC 29.0 (250) 6.0 (76) 31.0 (216) 11.0 (103)
CC 37.0 (431) 16.0 (135) 40.0 (375) 18.5 (168)
P 0.06 0.002 0.05 0.002
IL10 1082
AA 27.5 (138) 6.0 (36) 29.5 (120) 8.0 (52)
AG 33.5 (290) 15.5 (110) 37.0 (253) 16.0 (127)
GG 38.0 (191) 10.0 (55) 38.0 (159) 17.5 (78)
P 0.02† 0.2 0.1† 0.03†
IL6 174
CC 29.0 (120) 13.0 (39) 30.00 (98) 13.00 (56)
GC 32.0 (350) 13.0 (109) 34.00 (304) 13.00 (139)
GG 41.0 (207) 10.0 (63) 44.00 (184) 10.00 (76)
P 0.004† 0.9 0.01† 0.9
* Values are the median Larsen scores (number of carriers). Anti-CCP  anti–cyclic citrullinated peptide;
RF  rheumatoid factor; IL-10  interleukin-10.
† By Cuzick’s test for trend.
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the lowest scores in patients with the PTPN22 1858CC
genotype.
Dichotomized variables were created for both RF
and anti-CCP (for RF positive, 40 IU/ml; for anti-CCP
positive, 5.5 units/ml). Pearson’s chi-square test was
used to test for association between genotypes and
seropositivity. To determine whether the genetic associ-
ations with radiographic damage were secondary to the
production of RF and anti-CCP antibodies, genotypes
were compared between antibody-positive and antibody-
negative patients (Table 5). There was a weak associa-
tion of PTPN22 1858TT with anti-CCP positivity (P 
0.01); however, no other genotypes were significantly
associated with antibody production, indicating that the
genetic associations were independent of these well-
established markers of RA severity.
The relationship between antibody status, geno-
type, and radiographic damage was examined (Table 6).
Carriers of IL-10 –592 AC and AA were pooled together
because of small numbers. Homozygosity for IL-10
592C was associated with more severe radiographic
damage only in anti-CCP–negative patients (P  0.002)
and in RF-negative patients (P  0.002). Conversely, the
IL-6 174G allele was associated with more severe
disease only in anti-CCP–positive (P  0.004) patients
and RF-positive patients (P  0.01), with an allele-dose
effect. Marginally significant associations of PTPN22
1858T and IL-10 1082G were also detected.
Finally, the proportion of variance in modified
Larsen scores was calculated using the correlation coef-
ficient value (R
2). As expected in this cross-sectional
study, disease duration was the most significant (20%),
followed by RF (3%) or anti-CCP status (2%), IL-6
174 (0.8%), and IL-10 592 (0.4%).
DISCUSSION
Established biomarkers for RA severity include
RF, anti-CCP, and DRB1 genotypes; however, these
explain a relatively small proportion of the variance in
disease severity (9). Use of genetic markers predictive of
severity has several advantages over use of conventional
biomarkers; genotypes are stable, measurable at disease
onset, and are amenable to high-throughput assays.
Biomarkers can be used to measure inflammation load
or bone and cartilage turnover in RA; for example,
radiographic damage correlates with the time-averaged
C-reactive protein levels (8). New treatments of RA
have proven very effective for the treatment of severe
disease, but their more widespread use is limited by cost
in many countries. Clinically, there is a need to identify
additional markers that may be predictive of the out-
come of severe disease; such markers could be used to
target these new treatments to patients at risk of severe
RA. In this study, we examined the association of
functional genetic variants in 5 candidate RA genes with
radiographic damage, and evaluated whether associa-
tions were independent of established biomarkers.
The proinflammatory cytokine IL-6 has a range
of pleiotropic activities, including the induction of acute-
phase proteins, stimulation of T cells and B cells (includ-
ingthedifferentiationandactivationofimmunoglobulin-
producing plasma cells), and the stimulation of
synoviocytes and osteoclasts, with resultant damage to
cartilage and bone (16). High levels of IL-6 have been
reported in RA serum and synovial tissue (17). Further-
more, serum levels of IL-6 have been correlated with the
erythrocyte sedimentation rate and the platelet count
(18). Our finding of a gene-dose association of IL-6
174G with radiographic damage may be a conse-
quence of the higher gene expression that has been
associated with this allele (19). The IL-6 174G allele
has been associated with susceptibility to systemic-onset
juvenile RA in both a large case–control study (19) and
a family-based association study (20) but not with sus-
ceptibility to RA (21), although it has been associated
with a greater inflammation load in RA as assessed by
modified Disease Activity Scores as measured in 28
joints (22,23).
IL-10 is produced predominantly by monocytes
and lymphocytes and has a range of antiinflammatory
and immunoregulatory properties, including inhibition
of synthesis of proinflammatory molecules such as TNF,
IL-1, and IL-6 (24). Because of these properties, IL-10
was originally named cytokine synthesis inhibitor factor.
Production of IL-10 by rheumatoid synovial macro-
phages and T cells inhibits production of IL-1 and TNF
by synovial cells (25), and increased relative expression
of IL-10 has been reported in joints without erosion
compared with those with erosion, suggesting a protec-
tive role in RA (26).
Studies in animal models of RA have also dem-
onstrated an antiinflammatory role of IL-10 (27,28).
Genetic factors explain 75% of the population varia-
tion in IL-10 production (29). Secretion of IL-10 has
been correlated with individual promoter SNP geno-
types and haplotypes (30,31). Genotypes associated with
IL-10 production have been associated with susceptibil-
ity to RA (32); however, these findings have not been
replicated in other populations (33). Our data are
consistent with those from a Dutch prospective study of
2554 MARINOU ET AL91 female patients with RA followed up for 12 years, in
whom radiographic damage to the hands and feet pro-
gressed more rapidly in individuals homozygous for
1082G compared with those homozygous for 1082A
(26). Furthermore, this study also demonstrated lower
production of IL-10 in whole blood cultures of individ-
uals with the GG genotype compared with the AA
genotype, suggesting that the association of 1082G
with radiographic damage is related to lower IL-10
production.
Seropositivity for both RF and anti-CCP is asso-
ciated with development of more severe erosive RA (5),
raising the possibility that our findings of an association
of IL-6 and IL-10 genotypes with the modified Larsen
score may be secondary to the production of these
autoantibodies. However, RF and anti-CCP status was
not associated with IL-6 or IL-10 genotypes, indicating
that the genetic associations are independent of these
markers of radiographic damage.
In our study, the association between the Larsen
score and the IL-6 genotype was observed only in
patients who were RF negative and/or anti-CCP sero-
positive (i.e., patients with more severe disease). Con-
versely, the association between the IL-10 genotype and
the Larsen score was present only in patients who were
RF negative and/or anti-CCP seronegative (i.e., those
with milder disease). These findings may allow insights
into the pathogenesis of RA, as well as having potential
clinical importance. On the basis of these results, we
propose that autoantibody-specific B cells occupy a
more upstream position in the processes resulting in the
development of RA, and that the influence of particular
cytokine polymorphisms on disease phenotype is depen-
dent on their presence or absence. This paradigm is
broadly aligned with several recent studies demonstrat-
ing the presence of antibodies preceding disease onset
(34). From a practical point of view, we suggest that the
potential clinical utility of genotyping for the IL-6 and
IL-10 polymorphism would depend on RF and anti-CCP
status.
The PTPN22 1858T allele has been associated
with susceptibility to autoimmune diseases including
systemic lupus erythematosus, type 1 diabetes mellitus,
Graves’ disease, and RA (4). An area of controversy
relates to the association of this variant with RF produc-
tion. Several groups of investigators reported a genetic
association restricted to RF-positive patients 4,35), while
other investigators reported that the association is inde-
pendent of RF status (36,37). We did not observe an
association of PTPN22 1858T with RF status but
detected an association of anti-CCP status consistent
with that reported by Plenge et al (35).
The cross-sectional design of this study using an
RA cohort with established disease did not permit us to
examine whether the IL-6 and IL-10 genotypes are
associated with a linear increased level of joint damage
over time rather than perhaps primarily being important
at an early time period; such an assessment will require
a prospective study design. Further large prospective
studies should clarify the clinical usefulness of genotyp-
ing for these SNPs, particularly their potential role in
therapeutic targeting of expensive antirheumatic drugs
to patients at risk of developing more severe RA.
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